E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Biochemically-relapsing prostate adenocarcinoma following radical prostatectomy. |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001186 |
E.1.2 | Term | Adenocarcinoma of prostate |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Phase I: To determine the maximum tolerated dose (MTD) and the phase II recommended dose (P2RD) of abiraterone acetate plus prednisone combined with radiotherapy and LH-RH agonist treatment in patients with biochemical relapse from prostate cancer following surgery.
Phase II: To determine the 3-year Biochemical Relapse-free survival
|
|
E.2.2 | Secondary objectives of the trial |
Phase I and II: • To determine the overall safety (3 years) profile • To define the 3-year Overall survival • To define the 3-year Metastases-free survival • Time to achieve PSA nadir
Ancillary research |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Ancillary research Phase I: • To assess testosterone and LH serum level variations during one month after abiraterone initiation • To explore circulating tumor cells
Phase II : • To assess testosterone and LH serum level variations during one month after abiraterone initiation • To explore circulating tumor cells • To explore castration-induced osteopenia • To assess the quality of life before, during and after study treatment (QLQ C30 PR25, IIEF)
|
|
E.3 | Principal inclusion criteria |
1. Histologically confirmed prostate adenocarcinoma
2. The patients should have undergone only surgery for localized prostate adenocarcinoma: pT2, pT3 or pT4 with bladder neck involvement
3. pN0: negative lymphadenectomy at the time of prostatectomy
4. At inclusion the patients should have no clinical signs of progressive disease and should be M0 (bone and pelvic scans).
5. ≥ 18 years of age with life expectancy ≥ 10 years
6. Performance Status (ECOG) ≤ 1
7. PSA ≤ 0.1 ng/ml after prostatectomy (dosage performed within 2 months after surgery)
8. PSA ≥ 0.2 ng/ml et ≤ 2 ng/ml at the time of inclusion
9. Elevation of PSA over three consecutive assays performed in the same laboratory, with a minimal interval of two months between assays, (PSA nadir level followed by two other progressive assays)
10. At least 6 months between surgery and biochemical relapse
11. Serum potassium ≥ 3.5 mmol/L in the 72 hours before first dose of abiraterone acetate
12. Serum creatinine < 1.5 x ULN or a calculated creatinine clearance ≥ 60 mL/min
13. Liver function: - Serum bilirubin < 1.5 x ULN (except for patients with documented Gilbert’s disease) - AST and ALT < 2.5 x ULN
14. Patients must be affiliated to a Social Security System.
15. Patient information and written informed consent form signed for both principal and additional research
16. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. |
|
E.4 | Principal exclusion criteria |
1. pN1: histologically-proven lymph node involvement at initial lymphadenectomy
2. Histology other than adenocarcinoma
3. Previous hormone therapy including prior therapy with ketoconazole or other CYP17 inhibitor(s) for prostate cancer.
4. Patients being treated within the last 14 days prior to inclusion with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A4 (Clarithromycin, Ketoconazole, Itraconazole, Voriconazole, Ritanovir, see appendix 11) or requiring those treatments during the study
5. Active or symptomatic viral hepatitis or chronic liver disease
6. Surgical or chemical castration
7. History of cancer, with the exception of basal cell carcinoma or any other cancer treated in the 5 years before inclusion and in complete remission.
8. Previous pelvic radiotherapy
9. Uncontrolled hypertension (defined as systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg). Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy (see appendix 10 for mandatory BP measurement guidelines)
10. Severe and moderate hepatic impairment (Child-Pugh class B and C)
11. Patients with severe and/or uncontrolled medical disease which could compromise participation in the study, such as, but not limited to: Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease or cardiac ejection fraction measurement of < 50 % at baseline
12. Known hypersensitivity to any of the study drugs or excipients.
13. Galactosemia, Glucose-galactose malabsorption or lactase deficiency
14. Patients with any psychological, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
15. Individual deprived of liberty or placed under the authority of a tutor.
16. Patients already included in another therapeutic trial with an experimental drug or having been given an experimental drug within a period of 30 days. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
hase I part: The main objective is to determine the maximum tolerated dose (MTD) and the phase II recommended dose. Determination of the MTD is based on the occurrence of DLT (Dose Limiting toxicity) The DLT evaluation period lasts 11 weeks starting from the radiotherapy initiation. Toxicities are assessed weekly during the DLT evaluation period and at every visit through a clinical assessment, laboratory examinations and an ECG every 3 months. Toxicities are scored according National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
Phase II part: The safety analysis for the phase II part will include those patients who received at least one dose of abiraterone and those treated in phase I treated at the dose carried forward in the phase II. Toxicities are assessed at every visit through a clinical assessment, laboratory examinations and an ECG every 3 months. Toxicities are scored according National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
EFFICACY ASSESSMENT: Phase II primary endpoint: To determine the 3-year biochemical relapse-free survival. Biochemical relapse will be retrospectively defined by the date of the first PSA elevation following the 6-month abiraterone treatment (PSA ≥ 0.5 ng/ml and 2 consecutive PSA increases over a 2-month interval). When PSA ≥ 0.5 ng/ml, 2 consecutive dosages have to be done over a 2-month interval to confirm biochemical relapse. If no biochemical relapse is observed, the 6-month assessment is then resumed. PSA assays must always be performed for each patient in the same laboratory. 3-year RFS is calculated from the date of inclusion until the date of first evidence of a documented biological progression and analyzed using Kaplan-Meier method.
Secondary endpoints: 3 year overall survival (OS). 3-year metastases-free survival. The time to achieve PSA. |
|
E.5.2 | Secondary end point(s) |
EXPLORATORY ASSESSMENT: Phase I and II: Testosterone and LH serum levels (all testosterone and LH assays must be done for each patient in the same laboratory) Number of circulating tumor cells (CTC). Phase II: Bone density. Quality of life is assessed using the QLQ-C30, PR25 and IIEF questionnaires |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Phase I: • To assess testosterone and LH serum level variations during one month after abiraterone initiation • To explore circulating tumor cells
Phase II : • To assess testosterone and LH serum level variations during one month after abiraterone initiation • To explore circulating tumor cells • To explore castration-induced osteopenia • To assess the quality of life before, during and after study treatment (QLQ C30 PR25, IIEF) |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
determine the maximum tolerated dose |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |